Vidanex is rapidly gaining recognition for its groundbreaking work in the field of AI-powered cancer diagnostics. As a spin-off company from the IMU University, Vidanex is developing innovative solutions that are poised to transform cancer care by enabling faster and more accurate diagnoses, leading to earlier detection and personalized treatment strategies.
Vidanex's AI-Powered Solution: VIDAPath + AI
At the heart of Vidanex’s success is its cutting-edge AI-powered pathology solution, VIDAPath + AI. This one-stop digital pathology solution empowers pathologists to detect and diagnose cancer anytime, anywhere. VIDAPath + AI significantly enhances the accuracy and efficiency of cancer diagnosis, outperforming traditional methods that are often hindered by misdiagnosis and lengthy turnaround times.
Vidanex's Impact: Addressing the Global Cancer Challenge
With the global incidence of cancer projected to double by 2040, the need for innovative diagnostic solutions like VIDAPath + AI is more critical than ever. Vidanex is directly addressing this challenge by developing AI-enabled solutions that not only diagnose cancer but also predict patient outcomes and suggest personalised treatment options. Vidanex’s commitment to advancing precision medicine, particularly for those in remote areas with limited access to specialised healthcare, positions the company as a leader in the fight against cancer.
Vidanex's Journey: From Concept to Recognition
Since its inception in November 2023, Vidanex has rapidly achieved significant milestones, marking its journey from a promising concept to a recognised innovator in cancer diagnostics:
- First Spin-off Company from IMU University:
Vidanex made history as the first company to spin out from IMU, showcasing the university’s commitment to fostering innovation and translating research into real-world solutions.
- Showcased to the Prime Minister of Malaysia:
In a testament to its potential impact, Vidanex had the opportunity to present its technology to the Prime Minister of Malaysia, highlighting the company’s contribution to the country’s advancement in healthcare technology.
- Pilot Projects with Major Hospitals in Malaysia:
Vidanex secured pilot projects with hospitals in Malaysia, demonstrating the practical applicability and potential benefits of VIDAPath + AI in real-world clinical settings.
Vidanex's Success in Accelerator Programmes
- MRANTI’s Global Accelerator Programme (GAP) 2024 Champion:
Vidanex emerged as a winner in MRANTI’s GAP 2024, a programme focused on supporting startups with high-impact solutions in key areas such as healthcare. This achievement highlights Vidanex’s commitment to developing technology that addresses pressing global challenges.
- Selangor Accelerator Programme (SAP) 2024 Winner:
Vidanex was also recognised as a winner in the Selangor Accelerator Programme (SAP) 2024, specifically in the vertical focusing on Biotech, Healthcare, Agritech, Net Zero, and Life Sciences. This win underscores Vidanex’s contribution to innovation within these crucial sectors.
- MYStartup Pre-Accelerator Cohort 4 Demo Day 2024 Winner:
Vidanex is recognised for its innovative solution and strong potential to disrupt the healthcare industry. This programme is powered by Cradle and WatchTower and Friends
These accelerator programme wins have provided Vidanex with valuable resources, including:
- Mentorship:
Guidance from experienced industry professionals, helping Vidanex refine its business strategies and navigate the complexities of the startup ecosystem.
- Investor Exposure:
Opportunities to connect with potential investors and secure funding to further develop and scale its technology.
- International Expansion Opportunities:
Pathways to expand its reach beyond Malaysia and make a global impact in cancer care.
The success of past participants in these programmes further strengthens the significance of Vidanex’s achievements.
Vidanex’s journey has also included presentations at major industry events, including London Tech Week, INTEL EXPO in Bangkok, and APACMed in Singapore, NIH AI DAY 2024, CRADLE PlugIN Conference 2024 and International Pathology Day 2024 in Malaysia, providing the company with valuable exposure and opportunities to connect with potential partners and investors. Additionally, Vidanex has received awards at events like ITEX 2024, further validating its innovative approach to cancer diagnostics.
Vidanex's Vision for the Future
Vidanex is committed to using AI to improve the lives of cancer patients worldwide. The company’s vision is to make precision medicine accessible to everyone, regardless of location or socioeconomic status. With its dedication to innovation, accessibility, and collaboration, Vidanex is poised to make a lasting impact in the fight against cancer.
